NCT03744793 - Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Infiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma With Glandular DifferentiationInfiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid VariantMetastatic Urothelial CarcinomaMTAP Negative

Interventions

DRUG

Avelumab

Given IV

DRUG

Pemetrexed

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER